Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V-01 booster in healthy participants
NCT05050474Phase 1Completed
- Sponsor
- Livzon Pharmaceutical Group Inc.
- Start
- Aug 2021
- Primary completion
- Feb 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of V-01 in coronavirus disease 2019 (COVID-19), sponsored by Livzon Pharmaceutical Group Inc. Primary endpoint: Immunogenicity Endpoints. Started Aug 2021; status: completed.
02
Drugs
V-01
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05050474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05050474.